LITS (Lite Strategy) Marketable Securities: $2.08 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LITS Lite Strategy Inc LITS
22 GF Score
Price $1.03
! 2 Warning Signs
View Full Analysis

What is Lite Strategy Marketable Securities?

Lite Strategy LITS +5.08% 22 Marketable Securities is $2.08 Mil as of Mar. 2026. GuruFocus rates LITS with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Lite Strategy's Marketable Securities for the quarter that ended in Mar. 2026 was $2.08 Mil.

Lite Strategy's annual Marketable Securities declined from Jun. 2023 ($83.79 Mil) to Jun. 2024 ($34.64 Mil) and declined from Jun. 2024 ($34.64 Mil) to Jun. 2025 ($0.00 Mil).

Lite Strategy  (NAS:LITS) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Lite Strategy Marketable Securities Related Terms

Lite Strategy Marketable Securities Historical Data

* Premium members only.

The historical data trend for Lite Strategy's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lite Strategy Marketable Securities Chart

Lite Strategy Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 144.88 137.51 83.79 34.64 0.00

Lite Strategy Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 2.08
LITS
22GF Score
Lite Strategy Inc LITS
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lite Strategy Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $2.08 Mil mean?
Lite Strategy (LITS) has a Marketable Securities of $2.08 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Lite Strategy and its competitors.
Is Lite Strategy's Marketable Securities too high?
Lite Strategy's current Marketable Securities is $2.08 Mil. Overall, Lite Strategy has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Lite Strategy's Marketable Securities compare to SGMO and LSTA?
Lite Strategy's Marketable Securities of $2.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Lite Strategy and its competitors. Lite Strategy's current Marketable Securities is $2.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lite Strategy stock overvalued right now?
Lite Strategy (LITS) has a current Marketable Securities of $2.08 Mil. The current Marketable Securities is $2.08 Mil. Lite Strategy's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Lite Strategy (LITS), the current Marketable Securities is $2.08 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lite Strategy Business Description

Other Exchanges 0JW9:UK
Address 9920 Pacific Heights Boulevard, Suite 150, San Diego, CA, USA, 92121
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
22GF Score

Get the complete analysis for LITS

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.03
Price